Status:
UNKNOWN
Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis
Lead Sponsor:
Assiut University
Conditions:
Lupus Nephritis
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic bene...
Detailed Description
Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic bene...
Eligibility Criteria
Inclusion
- lupus nephritis
Exclusion
- cardiac disease Thrombosis
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05432531
Start Date
June 1 2022
End Date
April 1 2023
Last Update
January 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Manal Hassanien
Asyut, Assuit, Egypt, 71111